Pexiganan Acetate

Authors: Lamb H.M.1; Wiseman L.R.1

Source: Drugs, Volume 56, Number 6, December 1998 , pp. 1047-1052(6)

Publisher: Adis International

Purchase options

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$68.55 plus tax      Refund Policy

OR

 
More like this?
Content Key:
Free Content - Free
New Content - New
Open Access Content - Open Access
Subscribed Content - Subscribed
Free Trial Content - Free Trial

Abstract:

utrif Pexiganan acetate (MSI 78) is a synthetic cationic peptide (22 amino acids) with antibacterial activity. It is an analogue of magainin 2, which is a host defence peptide isolated from frog skin.

utrif The drug is thought to act by disturbing the permeability of the cell membrane or cell wall.

utrif Pexiganan acetate has good in vitro activity against Gram-positive and Gram-negative aerobes; 99% of strains were susceptible to the agent using a break-point of 64 mg/L. 89 to 97% of anaerobes were susceptible to pexiganan acetate using the same break-point.

utrif After 7 passages in vitro, there was no evidence of resistance to pexiganan acetate among 2 strains of Staphylococcus aureus.

utrif In 2 phase III multicentre randomised double-blind trials in diabetic patients with infected foot ulcers, both topical pexiganan acetate 1% and oral ofloxacin 800 mg/day achieved clinical cure or improvement in about 90% of patients.

utrif Eradication of pathogens in the 2 studies was achieved in 82% of ofloxacin recipients and 66% of pexiganan acetate recipients at the end of therapy.

utrif Limited data indicate that pexiganan acetate is well tolerated.

Keywords: Reviews-on-treatment; Pexiganan, general; Research-and-development; Gram-positive-infections, treatment; Gram-negative-infections, treatment; Topical; New-drug-profiles; Pexiganan, therapeutic-use; Pexiganan, antimicrobial-activity; Pexiganan, pharmacodynamics; Ofloxacin, antimicrobial-activity; Ofloxacin, therapeutic-use; Bacterial-infections, treatment; Antibacterials, general

Language: English

Document Type: New drug profile

Affiliations: 1: Adis International Limited, Auckland, New Zealand *

Back to top

Content Key:
Free Content - Free
New Content - New
Open Access Content - Open Access
Subscribed Content - Subscribed
Free Trial Content - Free Trial
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in
Need to register?
Sign up here
Text size: A | A | A | A